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Abstract
Tspan8 exhibits a functional role in many cancer types including pancreatic, colorectal, oesophagus carcinoma,
and melanoma. We present a first study on the expression and function of Tspan8 in breast cancer. Tspan8
protein was present in the majority of human primary breast cancer lesions and metastases in the brain, bone,
lung, and liver. In a syngeneic rat breast cancer model, Tspan8+ tumours formed multiple liver and spleen
metastases, while Tspan8− tumours exhibited a significantly diminished ability to metastasise, indicating a role of
Tspan8 in metastases. Addressing the underlying molecular mechanisms, we discovered that Tspan8 can mediate
up-regulation of E-cadherin and down-regulation of Twist, p120-catenin, and -catenin target genes accompanied
by the change of cell phenotype, resembling the mesenchymal–epithelial transition. Furthermore, Tspan8+ cells
exhibited enhanced cell–cell adhesion, diminished motility, and decreased sensitivity to irradiation. As a regulator
of the content and function of extracellular vesicles (EVs), Tspan8 mediated a several-fold increase in EV number
in cell culture and the circulation of tumour-bearing animals. We observed increased protein levels of E-cadherin
and p120-catenin in these EVs; furthermore, Tspan8 and p120-catenin were co-immunoprecipitated, indicating
that they may interact with each other. Altogether, our findings show the presence of Tspan8 in breast cancer
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primary lesion and metastases and indicate its role as a regulator of cell behaviour and EV release in breast
cancer.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
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Introduction
The need to enhance understanding of how metas-
tases develop and progress has initiated many studies.
The role of epithelial–mesenchymal transition (EMT)
has come to the fore, suggesting that a proportion
of primary tumour cells acquire mesenchymal prop-
erties to pass the basal membrane, disseminate into
the blood stream or lymphatic system, and colonise dis-
tant organs [1]. Based on this clinical observation, it
has also been proposed that a reverse process, so-called
mesenchymal–epithelial transition (MET), which trig-
gers cancer cell redifferentiation, takes place in a portion
ofmetastases and supports their growth [2]. Despite con-
troversial discussions and recent research showing that
EMT is not important for metastases but does play a
role in conferring chemoresistance in lung [3] and pan-
creatic cancer [4], a plethora of data support the occur-
rence of EMT–MET-like processes in breast cancer [5].
Whereas primary breast carcinomas, e.g. invasive ductal
carcinomas, express mesenchymal markers, their metas-
tases frequently exhibit epithelial features [6]. However,
the underlying mechanisms are not yet understood. In
this work, we propose a new function of Tspan8 as an
EMT–MET regulator in breast cancer.
Tetraspanins are transmembrane proteins that act as
membrane scaffolds contributing to the arrangement of
proteins in the cell membrane by organising so-called
tetraspanin-enriched microdomains (tetraspanin web)
[7]. Tetraspanin Tspan8 function is linked to the regu-
lation of cell motility, and is relevant for cancer progres-
sion. Up-regulation of Tspan8-coding mRNA has been
detected in colorectal, pancreatic [8], gastric [9], and
hepatocellular [10] carcinomas, as well as in melanoma
[11] and glioma [12]. It is likely that Tspan8 interacts
with different proteins in different tumour types. Thus,
in pancreatic cancer, CD9, CD151, CD44v6, and inte-
grins CD49c and CD49d, as well as intersectin and
clathrin, have been shown to be the main interacting
partners of Tspan8 [13]. In colorectal cancer, Tspan8
regulates cell motility and p120-catenin function by
interaction with E-cadherin [14]; recently, interaction of
Tspan8 with mephrin-βwas demonstrated [15]. Further-
more, targeting Tspan8 function may offer benefit as
a therapeutic intervention in ovarian [16] and colorec-
tal [17] carcinomas, hence attracting attention to this
molecule as a potential drug target. Recently, Tspan8
was identified as a biomarker for a subset of deeply
quiescent mammary stem cells (Lgr5+Tspan8hi), whose
transcriptome resembled claudin-low breast carcinoma
[18], thus indicating a potential role in breast cancer.
In this study, we analysed the expression of Tspan8 in
breast cancer in primary lesions and in metastases in
humans and examined its impact on the EMT–MET
programme in breast cancer cells and on the release and




Biopsies were acquired from breast cancer patients
and normal breast samples were obtained from individ-
uals undergoing plastic surgery. All samples were taken
after the study had been approved by the local ethics
committee and written informed patient consent had
been obtained. Immunohistochemistry was performed
as described in supplementary material, Supplementary
materials and methods.
In vivo model
Animal experiments were performed according
to regional and national guidelines and approved
by the ethics committee. Orthotopic injection of female
Fischer rats F344/DuCrl (Charles River, Sulzfeld, Ger-
many) was performed into a mammary fat pad (n= 5
per group, 1 × 106 cells). Animals were euthanised after
18 days; organs were prepared to control metastases,
and blood was used for extracellular vesicle (EV)
preparation as described in supplementary material,
Supplementary materials and methods.
Cell lines and cell assays
Detailed information regarding cultivation of differ-
ent cell lines under 2D and 3D conditions is pro-
vided in supplementary material, Supplementary mate-
rials and methods.
AFM-based single-cell force spectroscopy
A detailed description of the method is provided
in supplementary material, Supplementary materials
and methods.
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Figure 1. Legend on next page.
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Immunofluorescence
Cells were grown in eight-chamber slides (Ibidi,
Planegg, Germany), fixed, permeabilised, blocked
and incubated with a primary antibody (60min,
4 ∘C), washed three times, incubated with a
fluorochrome-conjugated secondary antibody (60min,
4 ∘C), mounted with Dako mounting medium, and
analysed using an LSM510 confocal microscope (Carl
Zeiss, Oberkochen, Germany).
Preparation of EVs
EVs were isolated and characterised according to the
MISEV requirements [19] as described previously [13]
(supplementary material, Supplementary materials and
methods; EV-TRACK database number MG3779JM).
Protein and RNA analysis
A detailed description of the method is provided
in supplementary material, Supplementary materials
and methods.
Statistics
All experiments were carried out in at least tripli-
cates (regardless of intra-assay triplicates) and statis-
tically evaluated by the two-tailed Student’s t-test or
Mann–Whitney. P values of less than 0.05 were con-
sidered significant.
Results
Tspan8 is expressed in breast cancer primary lesions
and in metastases in different organs
While the majority of tetraspanins are ubiquitously
expressed, in a healthy organism, the presence
of TSPAN8 is mainly restricted to the digestive tract
(Figure 1A) [20]. However, TSPAN8 is likely to be
up-regulated in different cancer types [21]. To address
the possibility of TSPAN8 playing a role in breast
cancer, we first tested seven breast cancer cell lines
(supplementary material, Table S4) [22] for TSPAN8
expression and observed that only MDA-MB-361
cells derived from brain metastases exhibited high
levels of TSPAN8. Other cell lines originating from
primary tumours or pleural effusions were found to be
Tspan8−/Tspan8low (Figure 1B). We also tested mRNA
isolated from cancer patient samples and detected
different levels of TSPAN8-coding mRNA in 4/7 pri-
mary tumours and 6/7 lymph node metastases, further
supporting a role for TSPAN8 in breast cancer (sup-
plementary material, Figure S1). Subsequently, we
examined the MDA-MB-231 model, consisting of the
parental cell line and two derivatives – 231-BR cells,
representing a brain-seeking clone [23], and 231-BCS60
cells, representing a bone-seeking clone [24]. In this
model, TSPAN8 was expressed significantly higher
in the brain-seeking 231-BR cells than in the parental
and the 231-BSC60 cells (Figure 1C), indicating that
expression of TSPAN8 may vary in the primary tumour
and its metastases.
These first observations prompted us to perform
immunohistochemistry in 27 primary human tumours
(16 ductal carcinomas, seven lobular carcinomas, and
four carcinomas in situ) and in 53 metastases from
different organs (30 brain, nine liver, eight bone, and
six lung metastases). TSPAN8 was detected in 24/27
primary lesions and in 41/53 metastases; specifically,
18/30 brain metastases and all of the liver, bone, and
lung metastases showed TSPAN8-specific staining
(Table 1 and Figure 1D). The specimens exhibited a
heterogeneous signal and by 5–80% positive cells, the
samples were considered positive.
It should be mentioned that to test for a link between
TSPAN8 expression in primary tumours and the
corresponding metastases, we were able to use 14
samples where both the primary tumour and the metas-
tases originated from the same patient (Table 1). Thus,
nine patients with brain metastases, three with liver
metastases, and two with bone metastases were exam-
ined (Table 1 and Figure 1D). We observed that the
expression levels of TSPAN8 in primary tumours and in
the corresponding metastases differed from each other,
indicating that expression thereof may change during
tumour progression.
Figure 1. Analysis of TSPAN8 expression in breast cancer cell lines and human tumours. (A) TSPAN8 mRNA expression was tested in
different organs in mice using RT-PCR. Highest expression was detected in the organs of the digestive system – stomach, intestine, and
colon – which exhibited 100-fold higher expression than in the other organs tested (see values on the y-axis). (B) TSPAN8 expression
was examined on RNA (upper panel) and protein levels (bottom panel) in seven breast cancer cell lines; GAPDH and vinculin were used
as loading controls for RNA and proteins, respectively. TSPAN8 was strongly expressed only in the MDA-MB-361 cells derived from
brain metastases. (C) MDA-MB-231 cell model, consisting of MDA-MB-231 parental cell line, 231-BR brain-seeking clone, and BSC60
bone-seeking clone, was tested for TSPAN8 (upper panel) and TSPAN8 protein (bottom panel) expression. The 231-Tspan8 cells – parental
cell line stably transfected with Tspan8, and MDA-MB-361-expressing endogenous Tspan8 were used as positive controls. Tspan8 revealed
strongest expression in the 231-BR cells. QPCR was performed in technical duplicates and biological triplicates; WB was repeated twice on
independent preparations. (D) Immunohistochemistry of human samples for TSPAN8 was performed on paraffin blocks and representative
specimens were chosen: on the upper panel, carcinoma in situ shows cytoplasmic localization of TSPAN8; four pairs of primary tumours
(pT1, pT2, pT3, pT4) and corresponding metastases (brain M1, brain M2, brain M3, liver M4) originating from the same patient exhibit
heterogeneous staining of TSPAN8 in primary tumours and in metastases. Right panel: a brain metastasis with strong membrane and
cytoplasmic TSPAN8 staining, a lung metastasis with strong membrane and cytoplasmic staining, and a bone metastasis with cytoplasmic
TSPAN8 staining are demonstrated. Arrowheads indicate cytoplasmic TSPAN8 and arrows membrane TSPAN8. Scale bar= 20 μm.
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Table 1. Immunohistochemistry for Tspan8 in breast cancer primary tumours and in their metastases
Primary











1 Poorly differentiated, invasive ductal 50% + – 1 Brain 20% + 10% +
2 Poorly differentiated, invasive ductal 50% + – 2 Brain – –
3 Poorly differentiated, invasive ductal – – 3 Brain 10% + –
4 Poorly differentiated, invasive ductal 70% + – 4 Brain – –
5 Poorly differentiated, invasive ductal – – 5 Brain – –
6 Moderately differentiated, invasive ductal – – 6 Brain – –
7 Moderately differentiated, invasive ductal 80% + – 7 Brain – 10% +
8 Moderately differentiated, invasive ductal – – 8 Brain – –
9 Poorly differentiated, lymphangio-invasive 80% + – 9 Brain 40% + 10%
10 Moderately differentiated, invasive ductal 80% + single + 10 Liver 80% + –
11 Moderately differentiated, NST 80% ++ – 11 Liver 80% + –
12 Poorly differentiated, invasive ductal 80%+ 10%+ 12 Liver 80% + –
13 Moderately differentiated, invasive lobular 90%++ single + 13 Bone 50%+ **/*** –
14 Moderately differentiated, invasive lobular 95%+++ – 14 Bone 90%+ */*** –
15 Moderately differentiated, invasive ductal 80%++ – No information
16 Well differentiated, NST 80%+ – No information
17 Well differentiated, invasive ductal 80%++ – No information
18 Moderately differentiated, NST 80%++ 5% No information
19 Moderately differentiated, NST 80%+ – No information
20 Poorly differentiated, invasive ductal 80%+ 20%+ No information
21 Moderately differentiated, invasive lobular 80%+ single + No information
22 Moderately differentiated, invasive lobular 80%+ – No information
23 Moderately differentiated, invasive lobular 80%++ – No information
24 DCIS (G2) 80%+ –
25 DCIS (G2) 80%+ 20%+
26 DCIS (G2) 80%+ 20%+
27 DCIS (G2) 80%+ single +
Moderately differentiated, invasive ductal 15 Brain 50% + –
Moderately differentiated, invasive ductal 16 Brain – –
Poorly differentiated, invasive ductal 17 Brain – –
Moderately differentiated, invasive ductal 18 Brain – –
Moderately differentiated, invasive lobular 20 Brain – –
Moderately differentiated, invasive lobular 21 Brain – –
Moderately differentiated, invasive lobular 22 Brain 50% + 50% ++
Moderately differentiated, invasive lobular 23 Brain – –
Moderately differentiated, invasive lobular 25 Brain – –
No information 26 Brain 80% +++ 40% ++
No information 27 Brain 80% + 5% +
No information 28 Brain 80% + –
No information 29 Brain 80% + –
No information 30 Brain 80% ++ 5% +
No information 31 Brain – –
No information 32 Brain 80% + –
No information 33 Brain 80% + –
No information 34 Brain 80% + –
No information 35 Brain 80% + –
No information 36 Brain 80% ++ –
No information 37 Brain 80% + 5% +
Invasive lobular 38 Liver 80% + –
Invasive ductal 39 Liver 80% + –
No information 40 Liver 80% + –
No information 41 Liver 80% + –
No information 42 Liver 80% + 5% +
No information 43 Liver 80% + Single +
Invasive NST 44 Lung 80% + 10% +
Invasive, NST 45 Lung 80% ++ 50% +
No information 46 Lung 80% + 50% +
No information 47 Lung 80% + –
No information 48 Lung 80% + –
No information 49 Lung 80% + –
Moderately differentiated, invasive NST 49 Bone 80% + Single +
Moderately differentiated, invasive ductal 50 Bone 80% + 30% +
No information 51 Bone 80% + –
No information 52 Bone 80% + –
No information 53 Bone 80% + Single +
No information 54 Bone 80% + 10% +
Data for TSPAN8 expression in the primary tumours and their corresponding metastases detected in the same patient are linked horizontally. Only analysed specimens
are numbered: thus, there are 27 primary tumours, and 54 metastases were examined.
70% +: 70% epithelium stained at low intensity; −: no TSPAN8 staining was detected.
Intensity was estimated as +, low; ++, moderate; and +++, strong by three pathologists.
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Overexpression of Tspan8 enhances cell–cell
adhesion and proliferation
To assess the direct impact of Tspan8 on breast cancer
growth and progression, we chose a syngeneic rat
breast cancer model. Overexpression of Tspan8 in the
MTPa [25] parental Tspan8-negative cells led to the
formation of compact cell clusters (Figure 2A). We
seeded the MTPa-pcDNA3 and MTPa-Tspan8 cells by
low density and tracked cluster formation for 12 h. Only
MTPa-Tspan8 cells established clusters, suggesting that
Tspan8 supports intercellular adhesiveness (Figure 2B).
Measurement of cellular adhesion forces using atomic
force microscopy by cell retraction [26,27] supported
this observation and showed that the MTPa-Tspan8
cells exhibit significantly stronger cell–cell adhesion
compared with the MTPa-pcDNA3 cells (Figure 2C).
In contrast, MTPa and MTPa-pcDNA3 cells displayed
faster cell–matrix adhesion to collagens I and IV,
while the MTPa-Tspan8 cells adhered significantly
faster to BME (human basement membrane extract)
(Figure 2D). The MTPa-Tspan8 cells exhibited approx-
imately three-fold higher efficiency of thymidine
incorporation, indicating that Tspan8 also supports cell
division (Figure 3E). A similar effect of Tspan8 was
observed in the MDA-MB-231 cells stably transfected
with Tspan8, indicating the similarity of Tspan8 action
in rats and humans (supplementary material, Figure S2).
In cell monolayers wounded by scraping the sur-
face, wound closure was significantly delayed in the
MTPa-Tspan8 cells compared with the parental and
MTPa-pcDNA3 cells (Figure 2F). Documentation of
wound healing by video microscopy revealed that
whereas single cells of MTPa and MTPa-pcDNA3
may abandon the cell population and migrate over
the scratch, some of the MTPa-Tspan8 cells migrate
along the population boundary, while the majority
of cells maintain cell–cell contacts, suggesting that
Tspan8 impairs wound closure by supporting cell–cell
adhesion and thereby preventing scattering of the cell
colonies (supplementary material, Movies S1 and S2).
Additionally, we compared the colony formation abil-
ity of MTPa-pcDNA3 versus MTPa-Tspan8 cells to
determine the impact of Tspan8 on the self-sufficiency
of a single cell. Performed under 2D conditions, MTPa
cells formed colonies of irregular shape and loose
cell–cell contact; in contrast, the MTPa-Tspan8 cells
formed tight round colonies, adding strength to the
hypothesis that Tspan8 plays a role in cell–cell adhesion
(Figure 2G, upper panel). Statistical analysis demon-
strated a slightly higher colony-forming ability of the
MTPa-pcDNA3 cells compared with the MTPa-Tspan8
cells (Figure 2G, bottom panel), suggesting that Tspan8
does not enhance the self-sufficiency of tumour cells
under conventional cell culture conditions.
Under 3D conditions, Tspan8 supports cell–cell
adhesion and proliferation in the presence of basal
membrane extract (BME), and mediates radiation
resistance
To test Tspan8 function under conditions more
closely resembling the physiological environment,
we employed conventional and customised 3D
cell cultures. To examine the ability of the cells
for anchorage-independent growth, an agarose liquid
overlay was used. The MTPa and MTPa-pcDNA3 cells
formed compact spheroids, whereas the MTPa-Tspan8
cells – in contrast to their behaviour under 2D condi-
tions – formed large aggregates with loose cell–cell
contacts, indicating impairment of the Tspan8 ability
to support cell–cell contact under the conditions
being tested (Figure 3A). Similar morphology of the
colonies was observed in a conventional soft agar
assay (Figure 3B, upper panel); quantitative analysis
revealed that Tspan8 overexpression causes a strong
reduction of the colony number (Figure 3B, bottom
panel), indicating diminished resistance to anoikis by
the MTPa-Tspan8 cells. Using recently characterised
agarose microwell arrays [28], we tested cell prolifer-
ation and observed that, in contrast to 2D, the Tspan8
proliferation-supporting effect was attenuated in a 3D
environment (Figure 3C).
Cancer progression involves ECM remodelling and,
vice versa, the ECM may mediate cancer cell behaviour
[29]. To address the impact of different ECMs on Tspan+
and Tspan8− cells, we employed a customised agarose
Figure 2. Tspan8 supports proliferation and cell–cell adhesion in breast cancer. (A) Upper panel: stable expression of Tspan8 in a rat breast
cancer cell line MTPa leads to changes in cell morphology (scale bar= 200 μm). Bottom panel: Tspan8 surface expression was assessed
using flow cytometry, which revealed 99% Tspan8+ cells. (B) Impact of Tspan8 on cell clustering was assessed. Cells were seeded at low
density and monitored for 12 h. The experiment was repeated three times. (C) Cell–cell adhesion was tested using atomic force microscopy.
Tspan8-expressing cells exhibited significantly higher adhesion forces than cells transfected with a control pcDNA3 plasmid. The analysis
on a single cell level revealed a high level of heterogeneity, showing strong variability of adhesive properties of single cells, resulting in high
error bars calculated as a standard error by statistical analysis. (D) Cell–matrix adhesion was tested on different substrates using pre-coated
24-well plates. Tspan8 expression resulted in a significant reduction of cell–matrix adhesion when no additional coating was used and on
the collagen I and IV matrixes; the BME coating resulted in a significant increase of cell–matrix adhesion of theMTPa-Tspan8 cells. (E) To test
cell proliferation, [3H]thymidine incorporation was measured. Tspan8 strongly supported cell proliferation. (F) Migration was tested using
time-lapse microscopy. Confluent cultures of the MTPa-pcDNA3 and MTPa-Tspan8 cells were used to produce a ‘wound’. Wound closure was
observed for 24 h. Videos are available in supplementary material, Movies S1 and S2. Quantitative analysis of cell-free areas performed using
ImageJ Plugin (right panel) showed that Tspan8 strongly reduces cell migration over the ‘wound’ (scale bar= 1000 μm). The experiment
was performed in biological duplicates and technical triplicates. p< 0.001 was considered as highly significant. (G) Colony-forming ability
was assessed by seeding 100 cells per 10 cm dish. While no significant difference in colony size was observed, Tspan8 mediated a slight but
significant reduction of colony-forming ability (scale bar= 500 μm).
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Figure 3. Tspan8 supports proliferation in BME ECM and mediates radiation resistance in a 3D environment. (A) To characterise aggregate
formation, 1000 cells per well were seeded in a 48-well plate coated with 1.5% agarose gel and monitored for 9 days. MTPa cells formed
tight cell aggregates, whereas the MTPa-Tspan8 cells lost their ability for cell–cell contact and formed loose cell aggregates (scale
bar= 200 μm). (B) Anchorage-independent growth was tested using soft agar colony formation assay. MTPa-Tspan8 cells formed about
300 colonies, whereas nearly 800 colonies were counted for MTPa-pcDNA3 cells, showing a strong negative effect of Tspan8 on anchorage
independence (scale bar= 500 μm). (C) A microwell array in six-well plates (upper panel) was used to test cell proliferation under 3D
conditions. For quantitative analysis, MTT staining (reflecting metabolic activity of the cells) was used (bottom panel). It showed a slight
reduction of proliferation/metabolic activity of MTP-Tspan8 cells compared with the MTPa-pcDNA3 cells (scale bar = 1000 μm). (D) Cell
invasion was tested in customised inserts (supplementary material, Figures S3 and S4) for 7 days without ECM (left panel), in collagen I
(middle panel), and in BME (right panel, scale bar = 500 μm). (E) Quantitative analysis of cell invasion revealed that in BME, MTPa-Tspan8
cells exhibit a significantly stronger proliferation than the parental MTPa-pcDNA3 cells, showing an increased growth rate after day 4.
(F) Gamma-irradiation resistance of 3D cell aggregate was tested using 137Cs with 0.66 Gy/min on day 2 as described in supplementary
material, Figure S5. A significantly higher number of the MTPa-Tspan8 aggregates grew upon irradiation than the MTPa-pcDNA3 aggregates.
All experiments, if not otherwise mentioned, were repeated at least three independent times.
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device allowing analysis of cell growth and behaviour
in a 3D environment inaccessible by conventional trans-
migration assays, allowing quantification of cell inva-
sion in 2D conditions (supplementary material, Figure
S3). Collagen I, which is the most abundant bone ECM
constituent [30], and BME, a cell culture-derived basal
membrane extract consisting of laminin, collagen IV,
and proteoglycans, and resembling the basal lamina
of internal organs, including the brain [31], were cho-
sen for the analysis. The MTPa cells formed compact,
rapidly proliferating aggregates in the control matrixes,
whereas the MTPa-Tspan8 cells formed slow-growing
clusters with loose cell–cell contacts (Figure 3D, left
panel). In the presence of collagen I, the MTPa, but
not theMTPa-Tspan8, cell spheroids formed outgrowths
and moved along the cavity, indicating a potential
for invasiveness (Figure 3D, middle panel and supple-
mentary material, Figure S3). The MTPa-Tspan8 cells
formed compact aggregates with a diminished prolifer-
ation ability (Figure 3D, middle panel). However, when
the cells were seeded into the BME, the MTPa-Tspan8
cells exhibited a significantly stronger proliferation than
MTPa (Figure 3D, right panel; 3E), further supporting
the importance of specific ECM components for Tspan8
function observed under 2D conditions.
Radiation resistance is the main obstacle to ther-
apeutic success in breast cancer metastases [32]. To
address the potential association of Tspan8 with radia-
tion resistance, we tested the colony-forming ability of
the MTPa-pcDNA3 and MTPa-Tspan8 cells upon expo-
sure to increasing radiation doses in 3Dmicrowell array.
Tspan8 strongly enhanced the resistance of cells to irra-
diation, mediating the survival of a higher number of
colonies (Figure 3F and supplementary material, Figure
S4). Similar results were obtained in human breast can-
cer cell lines when a radiosensitivity clonogenic survival
assay in 2D culture described elsewhere [33,34] was
performed (supplementary material, Figure S5). These
data supported a role of Tspan8 in radiation resistance
in breast cancer.
Tspan8 mediates a reversible change of cell
phenotype resembling the mesenchymal–epithelial
transition (MET)
To understand the molecular mechanisms behind
the observed phenomena, we analysed the signalling
pathways involved in the mechanisms of the Tspan8
action. Because the phenotypical changes mediated
by Tspan8 resembled mesenchymal–epithelial transi-
tion (MET), we tested for the expression of genes coding
for Twist, E-cadherin, β-catenin, and p120-catenin as the
main regulators of the EMT–MET programmes [1]. As
shown in Figure 4A, Tspan8 overexpression mediated
significant up-regulation of E-cadherin, which is char-
acteristic for epithelial cells, while Twist, β-catenin, and
p120-catenin, which are associated with mesenchymal
cell morphology, were significantly down-regulated.
Furthermore, expression of the β-catenin target genes
Axin2, LEF1, NKD1, and NKD2 [35] was completely
abolished in the MTPa-Tspan8 cells, indicating modula-
tion of β-catenin signalling upon Tspan8 overexpression
(Figure 4A). On the protein levels, E-cadherin and
Tspan8 were significantly increased, while p120-catenin
and cadherin-11, the regulators of mesenchymal cell
properties [36], were significantly decreased in the
MTPa-Tspan8 cells, supporting the notion that Tspan8
mediated MET (Figure 4B). Using immunofluores-
cence, we observed membrane localisation of Tspan8
and E-cadherin in the MTPa-Tspan8 cells (Figure 4C).
While p120-catenin and β-catenin exhibited cyto-
plasmic localisation in the MTPa cells, they were
detected on the cell membrane in the MTPa-Tspan8
cells (Figure 4C). Additionally, β-catenin-specific sig-
nals were observed in the nuclei of the MTPa, but
not MTPa-Tspan8, cells (Figure 4D, white arrows),
which together with the observed down-regulation of
the β-catenin target genes in MTPa-Tspan8 cells further
supported Tspan8-mediated modulation of the β-catenin
signalling pathway. Pronounced membrane staining of
Tspan8, E-cadherin, and catenins prompted us to test
their potential interaction. Co-immunoprecipitation
revealed E-cadherin- and p120-catenin-specific bands
in the Tspan8 precipitate. Tspan8 was also detected in
the E-cadherin precipitate together with p120-catenin
and β-catenin, indicating their association (Figure 4E).
Rescue of Tspan8-induced MET was tested by
Tspan8 and E-cadherin knockdown. Partial reversion
of the epithelial cell morphology was observed 72 h
after transfection with Tspan8- and E-cadherin-specific
RNA (Figure 4F, left panel). To control knockdown,
western blotting (WB) (Figure 4F, right upper panel)
and flow cytometry were performed (Figure 4F,
right bottom panel). Significant down-regulation
of Tspan8 and E-cadherin upon transfection with
Tspan8- and E-cadherin siRNAs was observed, indi-
cating their co-regulation; this was further supported
by up-regulation of p120-catenin and β-catenin in
both cases. Flow cytometry was performed 48 h after
transfection to examine surface expression of Tspan8
(Figure 4F, right bottom panel). The untreated cells
and cells transfected with control scrambled siRNA
showed 65% and 63% Tspan8 surface expression,
respectively (Figure 4F, right bottom panel, blue line,
green line). Following Tspan8 siRNA (red line) and
E-cadherin siRNA (orange line), the number of positive
cells was reduced to 32% and 47%, respectively. These
data were consistent with the gene expression analysis
(supplementary material, Figure S6).
Next, we tested co-regulation of TSPAN8 and
E-cadherin in MDA-MB-361 human breast cancer
cells expressing endogenous TSPAN8 and E-cadherin.
Knockdown of TSPAN8 and E-cadherin was per-
formed in MDA-MB-361 cells and examined by
immunofluorescence and flow cytometry (Figure 4G).
Heterogeneous TSPAN8 staining was observed in cells
transfected with control siRNA, and siRNAs specific for
Tspan8 and E-cadherin. Strong heterogeneity of fluores-
cence signals hampered their quantification. Therefore,
changes in TSPAN8 and E-cadherin surface expression
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following siRNA treatment were assessed by flow
cytometry (Figure 4G, bottom panel). The portion of
TSPAN8-strongly positive cells (Tspan8++/MFI> 105)
was reduced after siRNA transfection: 17% Tspan8++
cells were detected in non-transfected cells (blue line),
4.8% in Tspan8-siRNA transfected cells (red line), and
9.5% in E-cadherin (orange line) transfected cells. The
proportion of E-cadherin-positive cells (MFI> 103)
comprised 68.1% and 68% in the non-transfected
cells (blue line) and cells transfected with the control
siRNA (green line), respectively. E-cadherin surface
expression was reduced to 35.2% and 31% after trans-
fection with Tspan8 (red line) and E-cadherin-siRNA
(orange line), respectively. Co-regulation of Tspan8
and E-cadherin was also observed at the RNA level,
showing that E-cadherin is significantly reduced after
Tspan8 knockdown and, vice versa, Tspan8 was reduced
after E-cadherin knockdown (supplementary material,
Figure S7). However, in contrast to the MTPa cells,
neither p120-catenin nor β-catenin was affected by the
Tspan8 or E-cadherin siRNAs in the MDA-MB-361
cells (Figure 4H).
Tspan8 supports formation of metastases and EV
release in vivo
Next, we tested the effect of Tspan8 on the tumourigenic
properties of breast cancer cells in vivo. The MTPa and
MTPa-Tspan8 cells were injected orthotopically into
mammary fat pads of Fischer rats. No differences in the
growth of primary tumours were observed (Figure 5A,
upper panel). However, the MTPa-Tspan8 tumours
formed multiple metastases in the liver and spleen,
suggesting a role for Tspan8 in metastases in breast can-
cer (Figure 5A). A similar phenomenon was observed
when tumour cells were injected intraperitoneally
(supplementary material, Figure S8). Immunohisto-
chemistry showed Tspan8 staining in the MTPa-Tspan8
but not in the MTPa primary tumours (Figure 5B, upper
panel). No Tspan8 signal was observed in the livers of
rats harbouring the MTPa tumour (Figure 5B, middle
panel); the metastases-free spleen exhibited strong
fluorescence of endogenous Tspan8 (Figure 5B, bottom
panel). Weak and heterogeneous Tspan8 fluorescence
was observed in the liver and spleen metastases of rats
harbouring the MTPa-Tspan8 tumours (Figure 5B, right
panels).
Because extracellular vesicles (EVs) play an impor-
tant functional role in metastatic cancer progression
[37–39], and Tspan8 has already been shown to func-
tion as a modulator of EV release and function [13],
we examined the number of EVs in the blood of
tumour-bearing animals. Measurements by nanopar-
ticle tracking analysis (NTA) revealed a several-fold
increase in EV number in the blood of MTPa-Tspan8
animals (Figure 5C and supplementary material, Figure
S9). An even-stronger effect of Tspan8 was observed
after intraperitoneal injection of tumour cells (supple-
mentary material, Figure S10). Transmission electron
microscopy revealed vesicles of approximately 100 nm
diameter in the EV preparations from the blood of
animals harbouring MTPa and MTPa-Tspan8 tumours
(Figure 5D). Testing EVs by WB showed the exo-
somal markers Alix and CD9 on EVs in each of
the samples tested, indicating the presence of exo-
somes; however, only a very weak Tspan8 signal was
detected (Figure 5E). Since tetraspanins undergo strong
post-translational modifications [40], which may ham-
per protein detection by WB, we applied bead-assisted
EV measurement using flow cytometry [41] to examine
Tspan8. We detected Tspan8, CD9, and CD81 signals
on EVs isolated in control and in tumour-bearing ani-
mals. The EV level of CD9 was constant, consistent
Figure 4. Tspan8 induces mesenchymal–epithelial transition. (A) Total RNA was harvested from MTPa, MTPa-pcDNA3, and MTPa-Tspan8
cells, and expression of mRNA coding for E-cadherin, β-catenin, p120-catenin, Twist, and the β-catenin target genes Axin2, LEF1, NKD1,
and NKD2 was analysed by RT-qPCR. GAPDH was used as a reference transcript. Overexpression of Tspan8 resulted in up-regulation of
E-cadherin, highly significant down-regulation of β-catenin and p120-catenin, and complete abrogation of Twist1, Axin2, LEF1, NKD1, and
NKD2 expression. Technical duplicates and biological triplicates were analysed. (B) Cell lysates were prepared from MTPa, MTPa-pcDNA3,
and MTPa-Tspan8 cells. WB analysis confirmed the presence of E-cadherin. Densitometry analysis of protein signal intensity performed
by ImageJ revealed significantly diminished levels of p120-catenin and cadherin-11 in the MTPa-Tspan8 cells. No significant regulation
of β-catenin at the protein level was observed. The experiment was repeated five times. (C) Immunofluorescence analysis of the MTPa
and MTPa-Tspan8 cells. Cells were cultured for 24–48 h in chamber slides, fixed, and stained with the indicated antibodies. (D) Z-stack
of β-catenin staining was generated for MTPa and MTPa-Tspan8 cells. Red β-catenin-specific fluorescence was detected in the cytoplasm
and in the nuclei of MTPa cells, but not of MTPa-Tspan8 cells (small arrow in the Z-stack and arrowhead in the x/y flat bottom image).
Immunofluorescence was assessed four times independently. (E) Co-immunoprecipitation was performed in the MTPa-Tspan8 cell lysates
using antibodies specific to Tspan8, E-cadherin, p120-catenin, and β-catenin. As a negative control, cell lysates were incubated with the
corresponding isotype control mouse IgG and protein G Sepharose. The experiment was performed three times. (F) Rescue of Tspan8-induced
MET was tested by Tspan8 and E-cadherin knockdowns. Bright-field images were taken 72 h after siRNA transfection of MTPa-Tspan8 cells
with siRNA. To assess knockdown, proteins were harvested 48 h post-transfection, analysed by WB (right upper panel) and quantified
using ImageJ (right middle panel). To assess surface expression, flow cytometry was performed 48 h after transfection (bottom panel).
(G) Knockdown of Tspan8 and E-cadherin was performed in MDA-MB-361 cells followed by immunofluorescence and flow cytometry.
Heterogeneous Tspan8 staining was observed in cells transfected with control siRNA, and siRNAs specific for Tspan8- and E-cadherin. The
experiment was performed three times and representative images are shown. Changes in Tspan8 and E-cadherin surface expression after
siRNA were assessed by flow cytometry (bottom panel). The proportion of Tspan8 strongly-positive cells was calculated. The experiment
was repeated twice; representative diagrams are shown. (H) MDA-MB-361 cells were transfected with scramble-siRNA and Tspan8-siRNA;
proteins were harvested 48 h post-transfection and analysed by WB followed by densitometry analysis using ImageJ. Both Tspan8 and
E-cadherin were significantly down-regulated, while neither β-catenin nor p120-catenin was affected (bottom panel).
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Figure 5. Tspan8 supports metastases and mediates a significant increase in EV number in the circulation in vivo. (A) Orthotopic injection
of rats was performed using 1 × 106 MTPa or MTPa-Tspan8 cells per animal; cells were injected into the mammary fat pad (five animals
per group). At day 18, animals were sacrificed and organs isolated. Representative images of primary tumours, liver, and spleen are shown.
Pictures were taken and metastases counted using ImageJ. (B) Immunofluorescence was performed on frozen sections of primary tumours
and liver and spleen specimens from both the animals harbouring MTPa- and those harbouring MTPa-Tspan8 tumours. (C) EVs were collected
from rat blood and measured by NTA. Significantly higher numbers of EV were detected in the blood of rats injected with MTPa-Tspan8
cells. (D) Transmission electron microscopy of EV preparations revealed vesicular structures typical for EVs isolated from blood. (E) EVs were
lysed and equal amounts of proteins were loaded for WB analysis and tested with CD9, Alix, and Tspan8 antibodies. No differences in CD9
and Alix protein amounts were observed in control animals and in animals harbouring MTPa or MTPa-Tspan8 tumours. (F) Flow cytometry
analysis of EVs. Tspan8, CD9, and CD81 were tested and the percentage of positive EVs and the MFI value were counted. Strong differences
in the MFI values between the origin of EVs from control animals (green line) and the origin of EVs from MTPa (blue line) and MTPs-Tspan8
(red line) animals were noticed, showing a strong increase in the MFI of Tspan8 and CD81 in EVs derived from MTPa-Tspan8 animals. Flow
cytometry was performed twice and representative images are shown.
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with the WB data; however, the mean fluorescence
intensity (MFI) values for Tspan8 and CD81 were
strongly increased in EVs isolated from the blood of
MTPa-Tspan8 animals, compared with the MTPa and
control animals (Figure 5F and supplementary material,
Figure S11), which was consistent with the overall
increase in EV number in MTPa-Tspan8 animals.
Tspan8 modulates EV release and function in vitro
To test directly a role for Tspan8 in the regulation
of EV release, we isolated EVs from cultures of MTPa
or MTPa-Tspan8 cells. Electron microscopy showed
typical exosome-like structures of 60–100 nm diam-
eter in EV preparations (Figure 6A). Consistent with
the observations in vivo, NTA measurements showed
a significant increase in the number of EVs from
MTPa-Tspan8 cells compared with MTPa cells. We
observed both Tspan8- and E-cadherin-specific bands
in the MTPa-Tspan8 EVs tested by WB (Figure 6C).
Furthermore, recruitment of p120-catenin to EVs
was significantly increased in the presence of Tspan8
(Figure 6C). Therefore, we tested their potential inter-
action in EVs using co-immunoprecipitation. Similar
to the results in cells, E-cadherin and p120-catenin
were obtained in the Tspan8 precipitates (Figure 6D),
supporting their interaction in EVs. Additionally, inter-
action between E-cadherin, p120-catenin, and β-catenin
was detected. To test a direct contribution by Tspan8 to
recruitment of the E-cadherin/catenin complex to the
EVs, we transfected MDA-MB-361 cells with control
and Tspan8-specific siRNA (Figure 6E). We observed
a significant reduction of E-cadherin, p120-catenin,
and β-catenin in EVs after Tspan8 knockdown, further
corroborating our hypothesis. The function of these
EVs in tumour progression remains to be explored.
However, it is noteworthy that treatment of the parental
MTPa cells with EVs released by the MTPa-Tspan8
cells revealed their ability to suppress the expression of
p120-catenin and Twist encoding genes, and to diminish
the expression of β-catenin target genes in the parental
cells, adding strength to the hypothesis that Tspan8
impacts the EV amount and may have a role in the
regulation of EV content and function in breast cancer
(Figure 6F).
Discussion
On examining TSPAN8 expression in human breast
cancer specimens, we observed great variations
in the TSPAN8 expression levels within one specimen
and between primary lesions and metastases originating
from the same patient. Also, in the rat model, the liver
metastases revealed heterogeneous Tspan8 staining.
This observation is consistent with the overall models
of tumour heterogeneity and plasticity explaining vari-
ations occurring within one lesion as a consequence of
genetic and epigenetic changes during tumour progres-
sion, which allows cancer cells to adapt to a changing
microenvironment [42]. This model is completed by
the postulated intra-tumour hierarchy and cancer stem
cells (CSCs) [43,44]. It remains to be explored whether
Tspan8 may change the tumourigenic properties of
breast cancer CSCs; however, preliminary tests demon-
strated that TSPAN8 is not expressed in cultures of
the breast cancer stem-like cells (data not shown) [45].
Further investigation will be required to understand
the molecular mechanisms of TSPAN8 up-regulation
in breast cancer cells. Hence, several repressors and
activators of TSPAN8, such as GSK3β, IQGAP1, TPT1,
LCMR1, PTEN, and p53, were recently identified in
melanoma [46,47] which could potentially be involved
in the regulation of TSPAN8 expression in breast can-
cer. Thus, while wild-type p53 suppresses TSPAN8
expression [46], its somatic mutations occurring in
breast cancer [48] may be one of the reasons for the
re-expression of TSPAN8 in a portion of breast cancer
cells in primary lesions or metastases. Experimental
data will be required to test this hypothesis.
Furthermore, different intracellular locations of
TSPAN8 in the cytoplasm and on the membrane were
observed, as has already been described for colorec-
tal cancer [14]. Another tetraspanin, namely CD151,
was reported to exhibit membrane and cytoplasmic
localisation in breast cancer [49]. Because the intra-
cellular traffic routes and intracellular localisation of
tetraspanins are strongly dependent on external stim-
ulation [50], rearrangement of tetraspanin localisation
in tumour cells may have functional and, consequently,
therapeutic effects. Providing an answer to these
questions remains the subject of future investigations.
Here, we addressed the molecular mechanisms of
TSPAN8 action in breast cancer cells. Overexpressed
in breast cancer cells, Tspan8 induced E-cadherin
expression and mediated a strong down-regulation
of Twist and β-catenin target genes. Similar to col-
orectal cancer, co-immunoprecipitation experiments
showed the interaction between Tspan8, E-cadherin,
and p120-catenin [14]. However, whereas Tspan8 is
functionally linked to cell migration in colorectal can-
cer and abrogates E-cadherin function by collaborating
with p120-catenin and α2β1 integrin [14], in breast
cancer Tspan8 is likely to act together with E-cadherin,
regulating cell–cell adhesion and proliferation. Inter-
estingly, the role of E-cadherin as a tumour suppressor
was recently reconsidered because of its ability to
support metastatic potential and cell proliferation via
the activation of NF-κB [51]. The link between Tspan8
and NF-κB has not yet been explored. However, also
in other cancer types, Tspan8 can act as a regulator
of proliferation, motility, and invasiveness [9]. Simi-
larly, another tetraspanin, CD151, may exhibit multiple
effects including regulation of proliferation, motility,
and morphogenesis [52]. Furthermore, CD151 – mostly
characterised as a tumour- and metastasis-promoting
tetraspanin [53] – was also reported to build a complex
with the α3β1 integrin, suppressing ovarian tumour
growth by inhibiting Slug-dependent EMT and support-
ing cell–cell adhesion [54]. These data are consistent
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with the hypothesis that the biological effects of
tetraspanins are determined by their interacting partners
[55,56]. It seems that Tspan8 mediates cell motility via
collaboration with integrins α6β4 in pancreatic cancer
[57], α3β1 in gliomas [58], and α2β1 in colorectal
cancer [14]. Interaction with E-cadherin resulted in a
functional switch of Tspan8 in breast cancer. Along-
side increased cell–cell adhesion, Tspan8 supported
cell–matrix adhesion to the BME. Since cell–cell and
cell–matrix adhesion are functionally linked to each
other and involved, alongside cadherins, also integrins
[59], a connection between Tspan8 and integrins in
breast cancer, as is already known from other cancer
types [14,57,58], is possible. It may also explain the
observed increase of proliferation in the 3D matrix
in BME as a physiological response of the cells on
signalling across the adhesive network [59].
Addressing the question of the selective advan-
tages mediated by TSPAN8 in breast cancer, we
observed that Tspan8+ cells exhibit significantly greater
radiation resistance compared with control Tspan8−
mesenchymal-like cells, suggesting that MET may
also be linked to radiation resistance. In line with this
suggestion, up-regulation of Snail, an EMT trigger,
was linked to decreased radiation resistance in MCF7
cells [60]. Integrin α6, which is involved in radiation
resistance in breast cancer [61], may also be involved
in Tspan8-dependent radiation resistance as its inter-
acting partner [57]. Taking into account that cranial
radiation remains one of the leading therapies applied
for treatment of brain metastases [32], the presence
of Tspan8 may be critical for a response to radiation
therapy. Consequently, TSPAN8 inhibition, which has
been successfully tested for ovarian and colorectal
cancer with TSPAN8 inhibitory antibodies [16,17], may
be advantageous for therapy of TSPAN8 metastases.
In addition to regulation of the cell behaviour, Tspan8
mediated a substantial increase in the number of EVs
and contributed to the recruitment of its interacting part-
ners to the EVs, consistent with our earlier findings
[13]. In line with the evidence that Tspan8 may regu-
late EV content, we have also provided a useful first
indication of the function of these EVs, which will,
however, require further investigation. Positive results
for testing Tspan8 in EVs by flow cytometry and the
observed increase in Tspan8 fluorescence intensity in
EVs from the blood of Tspan8 tumour-bearing animals
indicate the first hint towards the potential of Tspan8 as
a non-invasive biomarker for breast cancer, which would
be useful to address in a clinical study.
To sum up, we have described here the first study
on TSPAN8 in breast cancer and have demonstrated
the impact of Tspan8 on adhesion, proliferation, radia-
tion resistance, and EV release. First hints towards the
molecular mechanisms of Tspan8 action and involve-
ment of E-cadherin were provided. These results warrant
further investigation of Tspan8 in breast cancer towards
the understanding of molecular mechanisms and test-
ing the value of Tspan8 as a therapeutic target and a
non-invasive biomarker.
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Figure 6. Tspan8 mediates increased EV release in vitro and supports recruitment of E-cadherin and catenins to EVs. (A) Transmission
electron microscopy of EVs released by the MTPa and MTPa-Tspan8 cells. Scale bar equals 500 nm in the large panel and 100 nm in the image
with higher magnification. (B) NTA was done with each of the samples isolated and a representative image is shown. Statistical analysis
of four independent measurements showed a highly significant increase in EV number (right panel). (C) EVs of MTPa, MTPa-pcDNA3, and
MTPa-Tspan8 cells were lysed and WB was performed. Densitometry showed a significant increase in the amount of Tspan8, E-cadherin,
and p120-catenin in EVs of MTPa-Tspan8 cells; for p120-catenin, a ratio of protein amount in EVs/protein amount in cells was calculated.
(D) Co-immunoprecipitation was performed in the MTPa-Tspan8 EVs using antibodies specific to Tspan8, E-cadherin, p120-catenin, and
β-catenin. As a negative control, EV lysate was incubated with the corresponding isotype control mouse IgG and protein G Sepharose. The
experiment was performed three times. (E) MDA-MB-361 cells were transfected either with control siRNA or with Tspan8-siRNA; EVs were
isolated 48 h post-transfection and analysed by WB followed by densitometry analysis using ImageJ. GAPDH was used as a loading control.
(F) Functional analysis with EVs released from the MTPa-Tspan8 cells was performed. The MTPa cells were treated daily with MTPa-Tspan8
EVs (5 μg/ml) for 5 days. As controls, MTPa cells were also treated with conditioned cell culture medium (MTPa-Tspan8 CM) and with
EV-depleted cell culture medium (MTPa-Tspan8 EV-depl CM) in order to discriminate between EV-specific and EV-non-specific effects. At
day 6, the cells were lysed and RNA was isolated and analysed using RT-qPCR. Expression of Tspan8, E-cadherin, β-catenin, p120-catenin,
Twist, and the β-catenin target genes Axin2, LEF1, NKD1, and NKD2 was examined. Significant down-regulation of p120-catenin, Twist,
NKD1, and NKD2, and up-regulation of Tspan8 were observed, indicating that MTPa-Tspan8 EVs may affect features of the MTPa parental
cells.
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